Annual revenue fell from KRW 35.2 billion in 2022 to KRW 26.8 billion in 2023, a decline of 23.8%, before rising to KRW 30.5 billion in 2024 (up 13.5%) and KRW 38.1 billion in 2025 (up 25.2%), marking two consecutive years of growth from 2024 through 2025.
In 2023, operating income turned to an operating loss of KRW 2.23 billion, and controlling-shareholder net income turned to a net loss of KRW 3.68 billion. In 2024, operating profit returned to KRW 621 million and controlling-shareholder net income was KRW 3.59 billion.
In 2025, operating profit rose 77.4% to KRW 1.1 billion, while controlling-shareholder net income fell 55.9% to KRW 1.58 billion. The company attributed the net income decline to lower foreign-exchange-related gains as currency volatility eased.
The operating margin went from 12.4% in 2022 to -8.3% in 2023, then 2.0% in 2024 and 2.9% in 2025, still well below the 2022 level.
The company cited higher U.S. male hormone diagnostic supply and the AAI Healthcare consolidation as drivers of 2025 profit growth, while U.S. tariffs and heavier marketing at the U.S. and German subsidiaries raised costs.
Operating cash flow went from KRW -646 million in 2023 and KRW -602 million in 2024 to KRW 4.15 billion in 2025. Quarterly results show an operating loss of KRW 65.06 million in the third quarter of 2025, followed by operating profit of KRW 909 million in the fourth quarter, a turn to profit.
In the first quarter of 2026, revenue was KRW 10.5 billion (down 17.0% from the previous quarter), with operating profit of KRW 149 million and controlling-shareholder net income of KRW 1.45 billion.
In the second quarter, revenue rose to KRW 12.5 billion (up 19.2% quarter on quarter) and operating profit to KRW 687 million.
In the third quarter of 2026, revenue was KRW 10.5 billion (down 16.2% from the prior quarter, up 22.5% year on year), with an operating loss of KRW 226 million, and a controlling-shareholder net loss of KRW 3.85 billion that was much larger than the operating loss, suggesting non-operating items had a large effect.
Controlling-shareholder net income over the latest four quarters totaled KRW 1.37 billion, and with swings this large quarter to quarter, full-year trends alone do not show the earnings base clearly.